Company news

SAB Biotherapeutics, Inc. news in 2025

SAB Biotherapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D

December 18, 2025

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

December 17, 2025

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

December 8, 2025

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

November 13, 2025

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

November 4, 2025

SAB BIO Highlights Data in Multiple Presentations at EASD

September 19, 2025

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

September 3, 2025

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

August 7, 2025

SAB BIO Announces Oversubscribed $175 Million Private Placement

July 21, 2025

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

May 9, 2025

SAB BIO Reports Full Year 2024 Operating and Financial Results

March 31, 2025

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

January 27, 2025

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

January 22, 2025

Decks in 2025